The Schall Law Firm, a renowned national shareholder rights litigation firm, has announced its investigation into claims on behalf of investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). The investigation centers around potential violations of securities laws, specifically focusing on allegations of false and/or misleading statements and the failure to disclose pertinent information to investors.
On September 19, 2023, the U.S. Food and Drug Administration (FDA) rejected ARS Pharmaceuticals’ epinephrine nasal spray, issuing a complete response letter (CRL) that requested additional efficacy and safety data from the company. This news had an immediate impact on ARS’s stock, causing a significant drop of nearly 55% in intraday trading on September 20, 2023.
The Schall Law Firm encourages shareholders who suffered losses to participate in the investigation. The firm’s founder, Brian Schall, is available to discuss their rights free of charge. The Schall Law Firm, known for its expertise in securities class action lawsuits and shareholder rights litigation, represents investors worldwide.
While the investigation is ongoing, it is important to note that the class in this case has not yet been certified. Shareholders who choose not to take any action will remain as absent class members until certification occurs. The Schall Law Firm aims to ensure that investors are properly represented and protected throughout the legal process.
ARS Pharmaceuticals, Inc., a company focused on developing innovative medical solutions, faced a setback with the FDA’s rejection of its epinephrine nasal spray. However, it is crucial to remember that this investigation is in progress, and no final conclusions have been reached regarding the alleged violations of securities laws.
Investors and industry observers will be keen to follow the developments of this investigation and subsequent legal proceedings. The outcome of this case may have implications for both ARS Pharmaceuticals and the broader pharmaceutical industry as a whole.
Please note that this press release from The Schall Law Firm may be considered Attorney Advertising in some jurisdictions under applicable law and rules of ethics.